|

Becotatug Vedotin Clinical Trials

6 actively recruiting trials

▲ +2 trials since July 2026

Also known as: MRG003

Pipeline

Phase 1: 1Phase 2: 3Phase 3: 2

Top Sponsors

  • Tianjin Medical University Second Hospital1
  • Sun Yat-sen University1
  • Ming-Yuan Chen1
  • Jiyan Liu1
  • First Affiliated Hospital of Guangxi Medical University1

Indications

  • Cancer6
  • Other EGFR-positive Pediatric Solid Tumors Deemed Eligible by the Investigator1
  • Diffuse Intrinsic Pontine Gliomas1
  • Atypical Teratoid/Rhabdoid Tumors1
  • Lymphoepithelial Carcinoma1

Other6 trials

A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma
Phase 2
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
Phase 3
EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer
Phase 2
Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases
Phase 3
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
Phase 1
Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.